Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Michael Kalos"'
Autor:
Yanxia Li, Nelusha Amaladas, Marguerita O’Mahony, Jason R. Manro, Ivan Inigo, Qi Li, Erik R. Rasmussen, Manisha Brahmachary, Thompson N. Doman, Gerald Hall, Michael Kalos, Ruslan Novosiadly, Oscar Puig, Bronislaw Pytowski, David A. Schaer
Publikováno v:
PLoS ONE, Vol 17, Iss 7 (2022)
Prolonged activation of vascular endothelial growth factor receptor-2 (VEGFR-2) due to mis-regulation of the VEGF pathway induces aberrant blood vessel expansion, which supports growth and survival of solid tumors. Therapeutic interventions that inhi
Externí odkaz:
https://doaj.org/article/9cc71a3eb98c45e392fe26cf507153e3
Autor:
Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos, Kyla E. Driscoll
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Abstract Background TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of particular intere
Externí odkaz:
https://doaj.org/article/add74ac3d1f847239e42c3dd99f9f142
Autor:
Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen, Gerald Hall, Jaafar N. Haidar, Dale L. Ludwig, Ruslan D. Novosiadly, Michael Kalos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Background Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable
Externí odkaz:
https://doaj.org/article/23eb068b1c80433fb11267b151e41edf
Autor:
David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R. Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A. Staschke, Linda A. Chung, Lacey M. Litchfield, Farhana F. Merzoug, Xueqian Gong, Philip W. Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D. Novosiadly, Michael Kalos
Publikováno v:
Cell Reports, Vol 22, Iss 11, Pp 2978-2994 (2018)
Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to inves
Externí odkaz:
https://doaj.org/article/1595454cd7fc4830988cdc917336d3e6
Autor:
Ruslan Novosiadly, Michael Kalos
Publikováno v:
Molecular Therapy: Oncolytics, Vol 3, Iss C (2016)
Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a b
Externí odkaz:
https://doaj.org/article/f09b254266364235bb5f8b77512e7457
Autor:
Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen, Gerald Hall, Jaafar N. Haidar, Dale L. Ludwig, Ruslan D. Novosiadly, Michael Kalos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-1 (2018)
Unfortunately, after publication of this article [1], it was noticed that corrections to the legends of Figs. 1 and 2 were not correctly incorporated. The correct legends can be seen below.
Externí odkaz:
https://doaj.org/article/fdf1b617c54c4afb9fbc0522a222a977
Autor:
Michael Kalos, Dale L. Ludwig, Gregory D. Plowman, Christopher M. Moxham, Ruslan D. Novosiadly, Jaafar N. Haidar, Andreas Sonyi, Darin Chin, Stacy Torgerson, Bing Han, Yanbin Lao, Tim Bailey, Danielle K. Bulaon, Yiwei Zhang, Xinlei Chen, Michael Topper, Sagit Hindi, Krishnadatt Persaud, Anthony L. Pennello, David Surguladze, Ivan Inigo, George Wang, Yang Shen, Scott W. Eastman, Carmine Carpenito, Maria Malabunga, Yiwen Li, Helen Kotanides
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell–mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1986ead76832948fc92b79c10618c0e0
https://doi.org/10.1158/2326-6066.c.6550090
https://doi.org/10.1158/2326-6066.c.6550090
Autor:
Michael Kalos, Dale L. Ludwig, Gregory D. Plowman, Christopher M. Moxham, Ruslan D. Novosiadly, Jaafar N. Haidar, Andreas Sonyi, Darin Chin, Stacy Torgerson, Bing Han, Yanbin Lao, Tim Bailey, Danielle K. Bulaon, Yiwei Zhang, Xinlei Chen, Michael Topper, Sagit Hindi, Krishnadatt Persaud, Anthony L. Pennello, David Surguladze, Ivan Inigo, George Wang, Yang Shen, Scott W. Eastman, Carmine Carpenito, Maria Malabunga, Yiwen Li, Helen Kotanides
Supplementary Figures 1-9 and Supplementary Tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae9b70f08e357e6f6d0737e3afa7b80
https://doi.org/10.1158/2326-6066.22542937.v1
https://doi.org/10.1158/2326-6066.22542937.v1
Autor:
Michael Kalos, Gregory D. Plowman, Dale L. Ludwig, Ruslan D. Novosiadly, Douglas Burtrum, Yiwei Zhang, Prachi Sharma, Lauren Boucher, Michael Topper, Andreas Sonyi, Darin Chin, Xinlei Chen, Amelie Forest, Anthony L. Pennello, Ivan Inigo, Leyi Shen, Colleen Burns, Jaafar N. Haidar, David Surguladze, Jingxing Li, Juqun Shen, Carmine Carpenito, Maria B. Lebron, Rose Marie Sattler, Helen Kotanides
Figure S3 shows CD137 receptor modulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3bb6a3afe5cfbbb01f18d1ddaccd41
https://doi.org/10.1158/1535-7163.22519410
https://doi.org/10.1158/1535-7163.22519410
Autor:
Carl H. June, Michael Kalos, Steven M. Albelda, Bruce L. Levine, Yangbing Zhao, Anne Chew, Gabriela Plesa, Michael C. Soulen, Drew A. Torigian, Marcela V. Maus, Andrew R. Haas, Gregory L. Beatty
Fig. S1. CARTmeso cell manufacturing and treatment schedules. Fig. S2. Detection of human anti-chimeric antibody responses in patients post-CARTmeso cell infusion. Fig. S3. Serum cytokines and chemokines in PDA patient 21211-101. Fig. S4. CARTmeso cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e0d6d8923a7103805d921bd44444646
https://doi.org/10.1158/2326-6066.22535990
https://doi.org/10.1158/2326-6066.22535990